Lifeline completes initial patient testing of ovarian cancer detection device

By Angela McDaniels

Seattle, Jan. 31 - Lifeline Biotechnologies Inc. said it has successfully completed the initial testing of the OvaScope, a micro endoscope used in the early detection of ovarian cancer.

"The initial product testing has been successfully completed [and involved] ten female patients in a gynecological oncology unit. The results are very encouraging and I was very pleased with the sharp image quality in each instance," lead investigator Kefah Mokbel said in a company news release.

"This micro endoscope transmits light through fiber optic bundles rather than rigid lens-based systems of traditional endoscopes. This process permitted direct vision in all patients tested," chief executive officer Jim Holmes said in the release.

"The data from these tests demonstrated that the OvaScope identified all patients with peritoneal disease and has value in gynecological oncology surgery," Holmes said.

There is currently no FDA-approved method for the early detection of ovarian cancer, the company said. Consequently, ovarian cancer is not usually detected until the very late stages of the disease and at a time when treatments are less successful and have a 30% survival rate.

Lifeline is a biotechnology company based in Reno, Nev.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.